el-Mekresh M M, el-Baz M A, Abol-Enein H, Ghoneim M A
Urology-Nephrology Centre, Mansoura, Egypt.
Br J Urol. 1998 Aug;82(2):206-12. doi: 10.1046/j.1464-410x.1998.00718.x.
To evaluate the outcome after the treatment of primary non-urachal vesical adenocarcinoma and to determine the significant prognostic factors.
The records of 185 patients with vesical adenocarcinoma were reviewed. The pathological evaluation included the determination of pathological stage, tumour grade, presence or absence of mucin and its location, evidence of bilharzial infestation and flow-cytometric DNA analysis. The mean follow-up of the treated patients was 3.1 years. Disease-free survival was estimated and the results correlated with patient and tumour characteristics (univariate analysis). Cox's proportional hazards analysis was used to determine prognostic factors.
The overall 5-year disease-free survival was 55%; only three factors had a significant impact on survival, the tumour pathological stage and grade, and lymph node involvement.
Radical cystectomy remains the only satisfactory treatment option for primary vesical adenocarcinoma. Tumour stage, grade and lymph node involvement are the only significant prognostic factors.
评估原发性非脐尿管膀胱腺癌的治疗效果，并确定重要的预后因素。
回顾了185例膀胱腺癌患者的病历。病理评估包括确定病理分期、肿瘤分级、黏液的存在与否及其位置、血吸虫感染证据以及流式细胞术DNA分析。接受治疗患者的平均随访时间为3.1年。估计无病生存率，并将结果与患者和肿瘤特征相关联（单因素分析）。使用Cox比例风险分析来确定预后因素。
总体5年无病生存率为55%；只有三个因素对生存有显著影响，即肿瘤病理分期和分级以及淋巴结受累情况。
根治性膀胱切除术仍然是原发性膀胱腺癌唯一令人满意的治疗选择。肿瘤分期、分级和淋巴结受累是仅有的重要预后因素。
